Long Covid breakthrough offers hope of new therapeutic target
Researchers from Yokohama City University in Japan have made a breakthrough in understanding Covid ‘brain fog’, providing clues for a new therapeutic target.
Researchers used a novel imaging technique to visualise AMPA receptors (AMPARs), key molecules for memory and learning, in the living brain. They discovered that higher AMPA receptor density in patients with Long Covid was closely tied to the severity of their symptoms, highlighting these molecules as potential diagnostic biomarkers and therapeutic targets.
Long Covid is a chronic condition that causes cognitive problems known as ‘brain fog’, but its biological mechanisms remain unclear. Previous imaging studies have shown some structural changes in the brain, but they could not pinpoint the molecular dysfunctions responsible for the cognitive symptoms. This has left scientists without objective biomarkers to confirm a Long Covid diagnosis or to develop therapies.
The research from Yokohama City University, published in Brain Communications, hypothesised that patients with brain fog might exhibit disrupted expression of AMPARs, based on prior research into psychiatric and neurological disorders such as depression, bipolar disorder, schizophrenia, and dementia.
Finding solutions for Long Covid
Researchers used a novel method called [C]K-2 AMPAR PET imaging to directly visualise and quantify the density of AMPARs in the living human brain. By comparing imaging data from 30 patients with Long Covid to 80 healthy individuals, the researchers found a notable and widespread increase in the density of AMPARs across the brains of patients. This elevated receptor density was directly correlated with the severity of their cognitive impairment, suggesting a clear link between these molecular changes and the symptoms.
The study’s findings represent an important step forward in addressing Long Covid. The systemic increase in AMPARs provides a direct biological explanation for the cognitive symptoms, highlighting a target for potential therapeutic treatments.
“Our findings clearly demonstrate that Long Covid brain fog should be recognised as a legitimate clinical condition,” said Professor Takuya Takahashi, who led the study. “This could encourage the healthcare industry to accelerate the development of diagnostic and therapeutic approaches for this disorder.”
“By applying our newly developed AMPA receptor PET imaging technology, we aim to provide a novel perspective and innovative solutions to the pressing medical challenge that is Long Covid.”
Bruno Quinney, Content Team, DDW
